Dabigatran

What is Dabigatran?

Dabigatran is a prescription medication that belongs to a class of drugs called direct oral anticoagulants (DOACs), also known as novel oral anticoagulants. It is used to prevent blood clots and reduce the risk of stroke in patients with certain heart rhythm disorders and other conditions. Dabigatran works by directly blocking a specific protein in the blood clotting process, making it less likely for dangerous blood clots to form.

Uses

Dabigatran is approved for several important medical conditions:

• Atrial fibrillation: Reduces stroke risk in patients with this irregular heart rhythm disorder who are not caused by a heart valve problem
• Deep vein thrombosis (DVT) treatment: Treats blood clots that form in deep veins, typically in the legs
• Pulmonary embolism treatment: Treats blood clots that travel to the lungs, a potentially life-threatening condition
• DVT and pulmonary embolism prevention: Prevents recurrence of these blood clots in patients who have been initially treated
• Hip or knee replacement surgery: Prevents blood clots following major orthopedic surgery in certain patients

How it works

Dabigatran is a direct thrombin inhibitor, meaning it blocks thrombin, a key enzyme in the blood clotting cascade. By specifically targeting and binding to thrombin, dabigatran prevents the conversion of fibrinogen to fibrin, which is essential for blood clot formation. This mechanism provides predictable anticoagulation without requiring routine blood monitoring, unlike older anticoagulants such as warfarin.

Side effects

Common side effects include:

Submit Your Paper

• Bleeding (minor bruising, nosebleeds)
• Stomach pain or discomfort
• Indigestion or heartburn
• Nausea
• Diarrhea
• Back pain
• Headache
• Dizziness

Serious side effects requiring immediate medical attention:

• Major bleeding (gastrointestinal, intracranial, or other serious bleeding)
• Signs of severe bleeding (unusual weakness, dizziness, headache, swelling)
• Blood in urine or stool
• Severe allergic reactions (difficulty breathing, swelling of face or throat)
• Symptoms of stroke despite treatment

Warnings and precautions

• Bleeding risk: Patients with active bleeding, recent surgery, or high bleeding risk should not use dabigatran
• Kidney function: Dose adjustments or avoidance necessary in patients with severe kidney disease, as the drug is primarily eliminated through the kidneys
• Pregnancy and breastfeeding: Not recommended during pregnancy or breastfeeding due to potential risks to the developing baby
• Surgery and procedures: Must be temporarily discontinued before elective surgery or invasive procedures to reduce bleeding risk
• Mechanical heart valves: Not recommended for patients with prosthetic heart valves or rheumatic mitral stenosis

Interactions

Several medications and substances can significantly interact with dabigatran:

• P-glycoprotein inhibitors (ketoconazole, dronedarone): Increase dabigatran levels, raising bleeding risk
• P-glycoprotein inducers (rifampin, St. John’s wort): Decrease dabigatran effectiveness
• Other anticoagulants (warfarin, heparin): Significantly increase bleeding risk when used together
• Antiplatelet agents (aspirin, clopidogrel): Increase bleeding risk, requiring careful monitoring
• NSAIDs (ibuprofen, naproxen): May increase bleeding risk, especially with long-term use
• Proton pump inhibitors: May slightly reduce dabigatran absorption
• Quinidine: Increases dabigatran levels and bleeding risk
• Verapamil: Can increase dabigatran exposure, potentially requiring dose adjustment

Check interactions with the GMJ Interaction Checker

Dosage

Dabigatran dosing varies based on the condition being treated and patient factors:

• Atrial fibrillation: Typically 150 mg twice daily; reduced to 75 mg twice daily in patients with kidney impairment
• DVT/PE treatment: Usually 150 mg twice daily after initial treatment with a parenteral anticoagulant
• DVT/PE prevention: Generally 150 mg twice daily for extended treatment
• Post-surgical prophylaxis: Varies by procedure and patient risk factors

Dosage adjustments are necessary for patients with reduced kidney function, advanced age, or other risk factors. Healthcare providers determine the appropriate dose based on individual patient characteristics and medical history.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).